Pharmacological Treatment of Acute Coronary Syndromes (Current Cardiovascular Therapy)

ABOUT THIS BOOK

· Presents highly practical information on conventional and newer treatment options for ACS
· Emphasis is on a just-the-facts clinical approach to the pharmalogic treatment of ACS
· Discusses recommendations for antiplatelet and anticoagulant agents in the treatment of ACS patients

This book updates clinicians on the most recent data regarding the medical management of patients of acute coronary syndrome (ACS), providing useful information and expert opinion on the large trials, international guidelines, and clinical practice. It reinforces the need for rapid intervention with pharmacologic therapies to treat and prevent coronary thromboembolism, and to prepare the patient for revascularization procedures, especially percutaneous coronary intervention.

Pharmacological Treatment of Acute Coronary Syndromes describes conventional treatment – including anti-ischemic, antiplatelet and anticoagulant therapy – and discusses the clinical use of newer treatment options: the potent new P2Y12 platelet receptor inhibitors with the recently recommended ticagrelor and prasugrel, and new oral anticoagulant agents showing promise for acute management and secondary prevention in ACS. Triple therapy, while not initiated in the acute setting, may impact on future surgical and medical emergencies and their management. Also covered are the various recommendations for each of the antiplatelet and anticoagulant agents in terms of patient selection, pretreatment and timing of therapy, making this book an essential read for a wide range of health professionals.

Content Level » Professional/practitioner
Keywords » Acute Coronary Syndromes - Cardiac Pharmacology - Cardiology
Related subjects » Cardiology & Angiology - Pharmacology & Toxicology

TABLE OF CONTENTS

Foreword.- Preface.- Anti-ischemic Therapy.- Antiaggregant Therapy: New potent P2Y12 inhibitors.- Anticoagulation Therapy: Heparins and Factor Xa inhibitors.- Secondary prevention in ACS The role of novel oral anticoagulants.- American vs European guidelines.- Critical appraisal.- Triple therapy: Risky but sometimes necessary.- Management of bleeding complications.

AUTHORS & EDITORS

Pablo Avanzas, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain, and Peter Clemmensen, Department of Surgery and Internal Medicine, University of Copenhagen, Denmark.